NEMA tries to derail GMP revision
The Food and Drug Administration wants to revise the good manufacturingpractices (GMP) regulations in the U.S., calling them out of stepwith European quality assurance standards. The National ElectricalManufacturers of America has proposed an
The Food and Drug Administration wants to revise the good manufacturingpractices (GMP) regulations in the U.S., calling them out of stepwith European quality assurance standards. The National ElectricalManufacturers of America has proposed an alternative. Rather thanrewrite existing rules, why not just adopt the European standards?
"NEMA is concerned that the FDA's proposed changes tothe medical device GMP greatly exceed the requirements of Europeanquality assurance," said Robin Wiley, NEMA spokesperson.Rather than fight over the proposed changes, NEMA has focusedon the stated goal of the FDA: to bring rules in this countryinto harmony with those in Europe.
"(Adopting the standard) would pave the way for GMP inspectionand certification agreements with the European Community,"said Robert Britain, director of the NEMA diagnostic imaging andtherapy systems division. "Since Canada has proposed thatits GMP will be based on ISO 9001, (the same) would also be possiblewith Canada," Britain wrote in a Feb. 28 letter to the FDA.
NEMA has taken the position that its proposal is consistentwith the Congressional establishment of an office of internationalrelations within the FDA. The office is supposed to facilitatemutual recognition of quality assurance standards among countries,according to Wiley.
Newsletter
Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.
Study Shows Enhanced Diagnosis of Coronary Artery Stenosis with Photon-Counting CTA
July 10th 2025In a new study comparing standard resolution and ultra-high resolution modes for patients undergoing coronary CTA with photon-counting detector CT, researchers found that segment-level sensitivity and accuracy rates for diagnosing coronary artery stenosis were consistently > 89.6 percent.
FDA Expands Approval of MRI-Guided Ultrasound Treatment for Patients with Parkinson’s Disease
July 9th 2025For patients with advanced Parkinson’s disease, the expanded FDA approval of the Exablate Neuro platform allows for the use of MRI-guided focused ultrasound in performing staged bilateral pallidothalamic tractotomy.
